WO2011060083A1 - Methods and compositions for rapid treatment of otitis externa - Google Patents

Methods and compositions for rapid treatment of otitis externa Download PDF

Info

Publication number
WO2011060083A1
WO2011060083A1 PCT/US2010/056255 US2010056255W WO2011060083A1 WO 2011060083 A1 WO2011060083 A1 WO 2011060083A1 US 2010056255 W US2010056255 W US 2010056255W WO 2011060083 A1 WO2011060083 A1 WO 2011060083A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
antibiotics
lipid
antibiotic
otitis externa
Prior art date
Application number
PCT/US2010/056255
Other languages
French (fr)
Inventor
William R. Campbell
Neil E. Paulsen
Roland H. Johnson
Douglas I. Hepler
Original Assignee
Triad Specialty Products Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43992011&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2011060083(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to UAA201207023A priority Critical patent/UA111147C2/en
Priority to PL10830669T priority patent/PL2498792T3/en
Priority to RU2012124067A priority patent/RU2680137C2/en
Priority to EP10830669.7A priority patent/EP2498792B1/en
Priority to BR112012011017A priority patent/BR112012011017A2/en
Priority to CN201080051245.7A priority patent/CN102612372B/en
Priority to SI201031550T priority patent/SI2498792T1/en
Priority to MX2012005521A priority patent/MX2012005521A/en
Priority to DK10830669.7T priority patent/DK2498792T3/en
Application filed by Triad Specialty Products Llc filed Critical Triad Specialty Products Llc
Priority to NO10830669A priority patent/NO2498792T3/no
Priority to JP2012538954A priority patent/JP2013510861A/en
Priority to CA2780160A priority patent/CA2780160C/en
Priority to LTEP10830669.7T priority patent/LT2498792T/en
Priority to NZ599559A priority patent/NZ599559A/en
Priority to KR1020177023631A priority patent/KR101901083B1/en
Priority to ES10830669.7T priority patent/ES2645200T3/en
Priority to AU2010319538A priority patent/AU2010319538B2/en
Publication of WO2011060083A1 publication Critical patent/WO2011060083A1/en
Priority to IL219483A priority patent/IL219483A/en
Priority to ZA2012/03239A priority patent/ZA201203239B/en
Priority to HRP20171520TT priority patent/HRP20171520T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents

Definitions

  • the present invention relates to non-invasive methods and compositions for treating otitis externa (outer ear infection or infestation and inflammation) without use of a cellulose viscocity-enhancing component, gel or adhesive-based formulation.
  • a variety of bacteria, viruses and fungi can be responsible for causing otits externa. Often first-line treatment is limited to oral or topical antibiotics. The use of orally
  • administered medications may be diluted by the systemic distribution of the drug, and could place the patient at risk for side effects associated with systemic delivery (e.g., yeast infections in females).
  • side effects associated with systemic delivery e.g., yeast infections in females.
  • the risk for fungal overgrowth in the ear canals of patients treated only with topical antibiotics for bacterial infections emphasizes a need for careful diagnosis and treatment of all the causative agents associated with otitis externa and its sequalae (Schraeder and Issacson, Pediatrics, 111 (5): 1123, 2003).
  • a preference is emerging for multiple agent topical treatment of otitis externa, especially in children and animals in whom compliance with a long-term oral dosing regimen can be difficult to obtain.
  • the invention provides a multiple agent composition for treating antibiotic or parasitic infections, fungal infestations, and inflammation which can be placed into and retained in the ear for a sufficient length of time to treat otitis externa without use of a gel, cellulose or other adhesive formulation.
  • formulations of the invention can be applied as infrequently as once, with an optional supplemental dosing, to resolve the treated condition entirely.
  • Preferred medicaments for delivery according to the invention are those useful in the treatment or prevention of otitis externa and its sequelae (such as pruritis).
  • the invention is particularly well-suited to the delivery of medicaments such as antibiotics or anti-viral agents (depending on the source of the infection present), anti-fungal agents, and antiinflammatory agents or other painkillers.
  • medicaments such as antibiotics or anti-viral agents (depending on the source of the infection present), anti-fungal agents, and antiinflammatory agents or other painkillers.
  • the methods of the invention may also be utilized between active infections to deliver prophylactic agents to the outer ear canal.
  • the present invention provides methods for topically treating and preventing otitis externa through administration of multiple active agents, preferably at least two and most preferably at least three active agents, which are useful in prophylaxis or treatment of external ear infections, infestations and inflammation.
  • topical administration is meant that a composition of the invention is applied to the external ear canal; i.e., on the outer ear side of the tympanic membrane (eardrum).
  • the compositions of the invention do not contain gelling agents, methylcellulose or other adhesive elements, yet are sufficiently potent to ameliorate or resolve otitis externa through a single dose course of treatment.
  • Topical administration to the outer ear canal is achieved via, for example, introducing the composition of the invention into the outer ear canal via any medically acceptable means; e.g., by applying the carrier composition to the membrane by insertion of a needleless syringe, dropper or swab into the auditory canal. Administration is repeated as required to achieve the therapeutically effective dosage level for the antibiotic compound given.
  • a particular advantage offered by the invention is that it enables
  • a follow up dose can be delivered after a medically suitable period of time.
  • 10 to 20 drops of a topical carrier composition could be delivered once, with a follow up dose at day 14 following treatment, or day 7 in the event of severe symptoms, if clinical observations of the patient's condition indicate that the first dose administered didn't completely resolve the condition.
  • Those of ordinary skill in the art will be familiar with, and readily able to select, dosing regimens suitable for following to treat a particular infection.
  • Presently preferred topical carriers for the actives applied according to the invention are those that are lipid-based, such as lipid emulsions (including microemulsions and oil-in-water emulsions), as well as lipid vesicles, such as liposomes, liosomes, micelles and transfersomes (ultraflexible lipid vesicles).
  • lipid-based formulations are presently preferred, especially for the non-vesicular formulations useful in the invention.
  • the medicament delivered according to the invention is preferably carried in a lipid phase (e.g., in the lipid bilayer of a liposome) rather than in an aqueous phase (e.g., in the core of a liposome).
  • lipid-soluble medicaments which can generally be provided at a higher concentration in the lipid layer of a vesicle than a water-soluble medicament dispersed in an aqueous phase can be) are preferred, though not required, for use in the invention.
  • liposome is meant a spherical lipid vesicle bounded by an ordered lipid bilayer and enclosing an aqueous phase.
  • the lipid bilayer of liposomes is usually made of natural or synthetic phospholipids, but can also be made of non-phospholipids.
  • the lipid bilayer of liposomes is an ordered bilayer, meaning that the molecular "head” and “tail” structures of the lipids are lined up next to one another.
  • Liposomes utilized in the present invention can be unilamellar (having one lipid bilayer) or more preferably are multilamellar. Liposomes that are "multilamellar" have multiple layers or membranes. This type of liposome has layers of lipid bilayers with an aqueous fluid spaced in between the lipid bilayers. Multilamellar liposomes have at least two layers of lipids.
  • Preferred liposomes are those described herein, and in commonly owned U.S. patent application Ser. No. 10/366,584, filed on Feb. 12, 2003, the disclosure of which is incorporated herein in its entirety, by this reference.
  • other formulations of liposomes may be utilized, including
  • phosphatidyl compounds such as phosphatidylglycerol, phosphatidylcholine,
  • phosphatidylserine phosphatidylethanolamine
  • sphingolipids cerebrosides
  • cerebrosides phosphatidylglycerols
  • diacylphosphatidylglycerols where the lipid moiety contains from 14- 18 carbon atoms, particularly from 16-18 carbon atoms, and is saturated.
  • Illustrative phospholipids include egg phosphatidylcholine, dipalmitoylphosphatidylcholine and distearoylphosphatidylcholine. Such lipids will also be useful in non- vesicular topical carrier compositions of the invention.
  • the size of liposomes and lipid vesicles utilized in the present invention may be variable, but such vesicles are preferably of uniform size in each batch preparation.
  • the liposomes may be up to 20 um, 25 ⁇ , or even 30 ⁇ . But in preferred embodiments about 95% of the liposomes will be from about 0.5 um to about 10 ⁇ in diameter. In one embodiment, at least 80% of liposomes in a preferred composition manufactured according to the methods described herein are from about 0.5 ⁇ to about 5 ⁇ . In this respect, the term "about” encompasses a range of 5% upwards or downwards from the stated value.
  • the liposomes can be multilamellar liposomes where a single larger liposome encapsulates one or more smaller liposomes.
  • compositions of the invention will preferably be preservative-free although, if necessary to the storage conditions, a water-soluble preservative may be utilized, such as a benezoic acid or a benzethonium salt (e.g., benzethonium chloride) or, most preferably, an oil-insoluble product such as DOWCILTM 200 (oil-insoluble 96% cis l-(3- chloroallyl)-3,5,7-triaza-l-azoniaadamantane chloride, Dow Biocides) or similar products known in the art, including other DOWCILTM branded products.
  • a water-soluble preservative such as a benezoic acid or a benzethonium salt (e.g., benzethonium chloride) or, most preferably, an oil-insoluble product such as DOWCILTM 200 (oil-insoluble 96% cis l-(3- chloroallyl)-3,5,7-triaza-l-azoniaa
  • compositions of the invention do not include any
  • viscosity enhancing or gelling agents an agent that is added to the composition to increase the viscosity.
  • a viscosity enhancing agent will increase the viscosity of a composition by at least 10,000 centipoise at 25° C.
  • Viscosity enhancing agents include, but are not limited to, methyl cellulose, hydroxypropyl methyl cellulose (HPMC), alginic acid, gelatin, acacia (gum Arabic) carbomer, and cetostearyl alcohol. Phospholipids are not considered viscosity enhancing agents within this definition.
  • the liposome is a phospholipid based vesicle, a preferred lipid will be
  • phospholipon 90H which is obtained and purified from soy lecithin and has the chemical name l,2-dia-cyl-5N-glycero-3 -phosphatidyl choline. It is minimum 90% phophatidyl choline and is fully hydrogenated.
  • the phosphatidylcholine can be of lower purity, or can contain other lipids or carrier materials such as, for example, propylene glycol/ethanol, medium chain triglycerides, oil/ethanol, phosphatidic acid, cholesterol, and phosphatidylinositol.
  • the phospholipid may be any natural or synthetic phospholipid, for example phosphatidylethanolamine, phosphatidylserine,
  • the phospholipid may be salted or desalted, hydrogenated or partially hydrogenated, natural, synthetic, or semisynthetic.
  • Examples of commercially available phospholipids include but are not limited to egg phospholipids PI 23 (Pfanstiehl, Waukegen, 111.), Lipoid E80 (Lipoid, Ludwigshafen, Germany); and the hydrogenated soy phospholipids Phospholipon 80H®, 80G®, 90H® and 100H®
  • dehydrated alcohol and propylene glycol can be used as co-solvents of the lipid phase, and vitamin E acetate can be included as an anti-oxidant.
  • vitamin E acetate can be included as an anti-oxidant.
  • other lipids or lipid-like substances are used in the invention, such as ceramides, lecithins, phosphatidyl ethanolamines, phosphatidyl serines, cardiolipins, trilinoleins and like compounds.
  • Nonphospholipids may also be used in the present invention.
  • nonphospholipid materials that may be useful include lipid vesicle forming polyoxyethylene fatty esters, polyoxyethylene fatty acid ethers, diethanolamines, long-chain acyl amides, long-chain acyl amino acid amides, long-chain acyl amides, polyoxyethylene sorbitan oleates, polyoxyethylene glycerol monostearates, glycerol monostearates, and mixtures, analogs, and derivatives thereof.
  • the vesicles may also include a steroid, and a charge producing agent.
  • Preferred steroids include cholesterol, hydrocortisone, and analogs, derivatives, and mixtures thereof.
  • Preferred negative charge producing materials are oleic acid, dicetyl phosphate, palmitic acid, cetyl sulphate, retinoic acid, phosphatidic acid, phosphatidyl serine, and mixtures thereof.
  • long chain amines e.g., stearyl amines or oleyl amines
  • long chain pyridinium compounds e.g., cetyl pyridinium chloride, quaternary ammonium compounds, or mixtures of these can be used, so long as the lipid vesicle can carry sufficient quantities of the aqueous phase.
  • liposomal formulations including non-phospholipid lipsomes
  • the multiphase liposomal drug delivery system disclosed in U.S. Pat. No. 4,761,288, issued Aug. 2, 1988 to Mezei is an exemplary representative of liposome compositions that may be utilized in the invention.
  • modification of the liposome (or other lipid vesicle utilized in the invention) to sterically stabilize the vesicle, or to provide for targeting, or to provide the vesicle (or other lipid-based carrier utilized) with slow release properties may interfere with the topical activity of the composition, and is therefore not preferred.
  • encapsulation efficiency is generally greater in liposomal compositions having a relatively high lipid:water content and a lipid-soluble drug carried in a lipid phase may generally be provided in a higher concentration than a water-soluble drug carried in an aqueous phase.
  • two or more ingredients can be encapsulated in the same vesicle, or if the active compounds are incompatible, the compounds can be encapsulated separately and the topical carrier compositions combined to provide a composition with two or more indications, or that treats a single indication with multiple active compounds.
  • a topical carrier composition including one or more active compounds for treatment of the outer ear canal encapsulated in a vesicle, and a second set of one or more active compounds for treating the auditory canal dispersed in unencapsulated form in a surrounding water phase.
  • a topical carrier composition including one or more active compounds for treatment of the outer ear canal encapsulated in a vesicle, and a second set of one or more active compounds for treating the auditory canal dispersed in unencapsulated form in a surrounding water phase.
  • non-vesicular lipids may be present, and all actives not encapsulated.
  • compositions of the invention are provided in a slow release form, such as in liposomes manufactured to resist degradation.
  • a slow release form such as in liposomes manufactured to resist degradation.
  • lipid phase see, e.g., U.S. Pat. No. 6,352,716, incorporated herein by reference as an illustration of a method for incorporating cholesterol into liposomes to this end).
  • Such relatively insoluble lipid vesicles can be expected to remain where delivered, to slowly release one or more of the active agents.
  • Such vesicles may also have disinfectant or other properties helpful in treating or controlling the rate of infection in the outer ear; e.g., if hexadecyl trimethylammonium bromide, a potent disinfectant, is utilized as a positive charge producing material within the vesicles provides a secondary advantage.
  • the vesicles act as a sustained release formulation as they each deteriorate.
  • active agent any biologically active compound useful in the treatment and/or prevention of otitis externa and its sequalae, as well as associated pain and inflammation.
  • particularly preferred medicaments are antibiotics useful in the treatment or prevention of otitis externa in mammals, especially humans.
  • antibiotics include, without limitation, amoxicillin (and other penicillins), ciprofloxacin (and other quinolone antibiotics, such as ofloxacin), clavulanate (and other beta-lactamase inhibitors), cefaclor (and other cephalosporins, such as cefixime), azithromycin (and other macrolide antibiotics, such as clarithromycin), and sulfisoxazole (as well as other sulfa drugs, such as sulfamethoxazole).
  • those that are highly lipid soluble, which may be water insoluble are preferred, with thiamphenicol and its analogues (e.g., chloramphenicol) being especially preferred.
  • compositions of the invention will contain multiple agents useful in treating otitis externa including, without limitation, anti-fungal and anti-inflammatory compounds.
  • Useful anti-inflammatory compounds for co-administration or use independent of antibiotic therapy include those that are sometimes less effective or well-tolerated in oral administration; e.g., non-steroidal anti-inflammatory drugs (NSAIDs), such as diclofenac, naproxen, ketoprofen, celecoxib, indomethacin, and pharmaceutically acceptable derivatives thereof.
  • NSAIDs non-steroidal anti-inflammatory drugs
  • Steroidal compounds may be administered as an alternative or additive to a NSAID when clinically indicated (e.g., in chronic cases of otitis externa with pruritis), but are not required for use in the invention.
  • the steroid may be betamethasone, betamethasone dipropionate, fluocinonide, fluocinoline acetonide, hydrocortisone, methylprednisolone, clobetasol, beclomethasone, dexamethasone sodium phosphate, triamcinolone and pharmaceutically acceptable derivatives thereof.
  • the pharmaceutically active agents provided will include an anti-fungal agent.
  • Suitable anti-fungal agents primarily include those that act on the cell wall or membrane of the fungi, although others (e.g., intracellularly acting agents) may also be suitable when clinically indicated.
  • cell wall/membrane active antifungals include the allylamines, the azoles, the polyene antimicotics, and the echinocandins.
  • Non-limiting specific examples include terbinafine, miconazole, ketoconazole,
  • terbinafine is the presently preferred anti-fungal agent for use in the invention.
  • the pharmaceutically active agent may also include a local anesthetic or analgesic agent.
  • suitable agents include benzocaine, benzyl benzoate, bupivacaine, calamine, chloroprocaine, chloroxylenol, cinchocaine, cocaine, dexivacaine, diamocaine, dibucaine, dyclonine, etidocaine, hexylcaine, ketamine, levobupivacaine, lidocaine, menthol, mepivacaine, oxethazaine, phenol, pramoxine, prilocaine, amethocaine, tetracaine, proparacaine, propoxycaine, pyrrocaine, resorcinol, risocaine, rodocaine, ropivacaine, tetracaine, and pharmaceutically acceptable derivatives thereof. Due to the rapid action of the compositions of the invention in resolving treated o
  • otitis externa is often linked to a parasitic infestation, most often an otocariosis, or Otodectes cynotis (ear mites) infestation.
  • Topical treatment with ear mites has often been accomplished with relatively long courses of topical insecticidal therapy; e.g., with a pyrethrin-containing composition.
  • mectin and mycin compounds e.g., avermectins (such as ivermectin and selamectin) and milbemycin, administered otically, by injection, or on the skin.
  • anti-parasiticidal compounds may be co-administered within, or as a separate adjunct to, the compositions of the invention.
  • anti- viral compounds such as acyclovir, may be administered in lieu of, or as an adjunct to, antibiotic compounds.
  • the invention may be utilized to treat otitis externa in any mammal, in whom the pharmaceutically acceptable, cellulose-free, non-gelled compositions of the invention will be applied topically to the outer ear canal in a dose sufficient to clinically ameliorate (significantly reduce symptoms to susceptibility to resolution with re-treatment, preferably a single dose re-treatment) or to resolve the treated condition.
  • concentrations and dosing ranges expected to be efficacious in most clinical situations and species are 0.1 to 2.0% active w/w, delivered in unit dosages of up to about 1 mis., or 10-20 drops depending on the clinician's judgment of the appropriate course of treatment and the strength of the dosage delivered.
  • the lipid carrier was prepared with phospholipon 90H, and the active/inactive ingredients listed admixed therewith to a volume of lOOg as follows.
  • aqueous phase water was added to a stainless steel jacketed vortex hydration chamber mixing vessel.
  • the vessel's chamber was covered to prevent evaporation of water and equipped with a bottom port and valve to regulate flow of material out of the vessel.
  • DOWCILTM 200 was added and dissolved into the water.
  • one-half of the thiamphenical was added and dissolved to the water, and heat applied to the mixture at 50°C.+- 2° C. Mixing was performed at low speed to avoid formation of a foam. As the mixture was heating, the diclofenac was added and mixed until dissolved.
  • a second stainless steel jacketed mixing vessel was utilized in close proximity to the first.
  • mixing of the propylene glycol, alcohol, cholesterol, vitamin E acetate, terbinafine and the remaining half of the thiamphenicol with the phospholipon 90H was initially performed slowly to avoid formation of foam or surface bubbles.
  • An overhead mixer was started and heat applied to raise the temperature of the mixture to between 55°C and 60°C until all were dissolved.
  • a cover was used on the chamber to prevent evaporation of alcohol throughout the procedure.
  • the lipid phase was quickly added to the aqueous phase at medium mixing speed.
  • valves were opened on the bottom ports of the chambers, and the flow was regulated from both vessels.
  • the aqueous phase and oil phase flowed and met at an in-line regulating tee, and a dispersing pump pulled the two phases together.
  • the mixture was circulated through a 60 mesh dispersing screen to optimize the hydration of the lipid phase.
  • the mixture was then directed to the top of the chamber and the entire process was circulated through the pump, back into the chamber for 10 minutes.
  • the chamber jacket was allowed to cool with continued slow mixing until the temperature of the product was 40° C, completing the process.
  • the combination of materials is preferably fast enough to mix thoroughly without causing formation of surface foam or bubbling.
  • the cooling process is preferably slow, with cooling of about 6°C per hour most preferable., by pouring or quickly pumping the former into the latter to mix them using bottom ports and tees. No heat was applied to the mixture.
  • the formulations prepared were as follows.
  • the endpoint for effectiveness was an clinical score improvement to 2 or less in both ears, with a presenting score of at least 6 per ear being a condition for admission of an animal into the study.
  • the clinical scores were objectively assigned and evaluated by a clinician based on a standard scoring system for each of the following signs of otitis externa: pain, erythema, exudate, swelling, odor, and ulceration.
  • 0 none
  • l mild/moderate— mild abrasions visible
  • 2 severe— abrasions extensive and/or may be bleeding.
  • R ⁇ Y yeast, retreated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Anesthesiology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Methods for treating and preventing otitis externa with a course of treatment consisting of as little as a single dose are provided. The methods are practiced by topical administration of compositions having a lipid carrier, such as liposomes and non- vesicular lipids, to the outer ear canal. Such compositions lack viscocity-enhancing celluloses or adhesives, and are preferably not in the form of a gel. Active agents useful for treating pain, inflammation, fungal or parasitic infestation and/or infections in the outer ear are co- administered in or with the composition.

Description

METHODS AND COMPOSITIONS FOR RAPID
TREATMENT OF OTITIS EXTERNA
FIELD OF THE INVENTION
[0001] The present invention relates to non-invasive methods and compositions for treating otitis externa (outer ear infection or infestation and inflammation) without use of a cellulose viscocity-enhancing component, gel or adhesive-based formulation.
BACKGROUND OF THE INVENTION
[0002] Millions of ariimals and people, especially children, are affected each year with otitis externa; i.e., infection and/or infestation of the outer ear, often accompanied by painful inflammation of the affected tissue. Animals with ear flaps, such as many breeds of dogs, are especially susceptible. Their covered outer ear canals provide an inviting environment for microbes to breed and inflammation to form, yet caretakers may not notice the condition as readily as in raised ear animals.
[0003] A variety of bacteria, viruses and fungi can be responsible for causing otits externa. Often first-line treatment is limited to oral or topical antibiotics. The use of orally
administered medications may be diluted by the systemic distribution of the drug, and could place the patient at risk for side effects associated with systemic delivery (e.g., yeast infections in females). Yet the risk for fungal overgrowth in the ear canals of patients treated only with topical antibiotics for bacterial infections emphasizes a need for careful diagnosis and treatment of all the causative agents associated with otitis externa and its sequalae (Schraeder and Issacson, Pediatrics, 111 (5): 1123, 2003). As such, a preference is emerging for multiple agent topical treatment of otitis externa, especially in children and animals in whom compliance with a long-term oral dosing regimen can be difficult to obtain.
[0004] When single or multiple active agents are applied topically to treat otitis externa, efficacy often depends on how long the medication can be maintained in contact with the affected tissue, especially when a fungal or parasitic infestation (e.g., ear mites) is present. Conventional ear drops are problematic because the tissues they contact is directly affected by the attitude of the patient's head, and the drops can easily flow out of the ear with movement. Approaches to increasing the residence time of topical medications in the external ear canal have included use of flowable gels made more adhesive with a cellulose (e.g., hydroxypropyl methylcellulose), gel plugs, mousses, foams, or other formulations with adhesive properties.
[0005] Yet compliance with dosing regimes using such formulations is again an issue, as their thick and/or sticky feel in the ear may be a source of frustration, especially to animals and young children. If acceptance of a retainable topical formulation isn't possible, the remaining option is often more frequent, and less convenient, dosing with less viscous solutions, such as conventional ear drops. A need, therefore, exists for an approach to topical treatment of otitis externa which doesn't rely on use of gels, cellulose-based or adhesive compositions, and which can be applied infrequently (i.e., once or twice as an entire course of treatment) to ameliorate (significantly reduce symptoms) or resolve the condition.
SUMMARY OF THE INVENTION
[0006] The invention provides a multiple agent composition for treating antibiotic or parasitic infections, fungal infestations, and inflammation which can be placed into and retained in the ear for a sufficient length of time to treat otitis externa without use of a gel, cellulose or other adhesive formulation. Surprisingly, it has been found that formulations of the invention can be applied as infrequently as once, with an optional supplemental dosing, to resolve the treated condition entirely.
[0007] Preferred medicaments for delivery according to the invention are those useful in the treatment or prevention of otitis externa and its sequelae (such as pruritis). The invention is particularly well-suited to the delivery of medicaments such as antibiotics or anti-viral agents (depending on the source of the infection present), anti-fungal agents, and antiinflammatory agents or other painkillers. For prevention of chronically recurring external ear infections, the methods of the invention may also be utilized between active infections to deliver prophylactic agents to the outer ear canal.
[0008] The summary of the invention described above is not limiting and other features and advantages of the invention will be apparent from the following detailed description of the preferred embodiments, as well as from the claims. DETAILED DESCRIPTION OF THE INVENTION
A. Methods for Topical Treatment of Otitis Externa
[0009] The present invention provides methods for topically treating and preventing otitis externa through administration of multiple active agents, preferably at least two and most preferably at least three active agents, which are useful in prophylaxis or treatment of external ear infections, infestations and inflammation. By "topical administration" is meant that a composition of the invention is applied to the external ear canal; i.e., on the outer ear side of the tympanic membrane (eardrum). The compositions of the invention do not contain gelling agents, methylcellulose or other adhesive elements, yet are sufficiently potent to ameliorate or resolve otitis externa through a single dose course of treatment.
[0010] Topical administration to the outer ear canal is achieved via, for example, introducing the composition of the invention into the outer ear canal via any medically acceptable means; e.g., by applying the carrier composition to the membrane by insertion of a needleless syringe, dropper or swab into the auditory canal. Administration is repeated as required to achieve the therapeutically effective dosage level for the antibiotic compound given. However, a particular advantage offered by the invention is that it enables
amelioration (substantial reduction of symptoms) or resolution (elimination of symptoms) of otitis externa with a course of treatment consisting of as little as one dose.
[0011] If the otitis externa proves to be unusually refractive to treatment, but the clinical symptoms of the condition are ameliorated after the first dose administered, a follow up dose can be delivered after a medically suitable period of time. For example, as demonstrated in Example 1 , 10 to 20 drops of a topical carrier composition could be delivered once, with a follow up dose at day 14 following treatment, or day 7 in the event of severe symptoms, if clinical observations of the patient's condition indicate that the first dose administered didn't completely resolve the condition. Those of ordinary skill in the art will be familiar with, and readily able to select, dosing regimens suitable for following to treat a particular infection.
B. Lipid-Based Carriers For Use In The Invention
[0012] Presently preferred topical carriers for the actives applied according to the invention are those that are lipid-based, such as lipid emulsions (including microemulsions and oil-in-water emulsions), as well as lipid vesicles, such as liposomes, liosomes, micelles and transfersomes (ultraflexible lipid vesicles). Phospholipid-based formulations are presently preferred, especially for the non-vesicular formulations useful in the invention.
[0013] Most preferably, the medicament delivered according to the invention is preferably carried in a lipid phase (e.g., in the lipid bilayer of a liposome) rather than in an aqueous phase (e.g., in the core of a liposome). Thus, lipid-soluble medicaments (which can generally be provided at a higher concentration in the lipid layer of a vesicle than a water-soluble medicament dispersed in an aqueous phase can be) are preferred, though not required, for use in the invention.
[0014] Methods for preparing lipid emulsions and vesicles are well-known in the art, and so will only be briefly outlined here with respect to the most presently preferred embodiment of topical carrier composition for use in the invention, a liposome prepared without a steric stabilizer, and without a viscocity-enhancing, gelling and/or adhesive agent.
[0015] By "liposome" is meant a spherical lipid vesicle bounded by an ordered lipid bilayer and enclosing an aqueous phase. The lipid bilayer of liposomes is usually made of natural or synthetic phospholipids, but can also be made of non-phospholipids. The lipid bilayer of liposomes is an ordered bilayer, meaning that the molecular "head" and "tail" structures of the lipids are lined up next to one another.
[0016] Liposomes utilized in the present invention can be unilamellar (having one lipid bilayer) or more preferably are multilamellar. Liposomes that are "multilamellar" have multiple layers or membranes. This type of liposome has layers of lipid bilayers with an aqueous fluid spaced in between the lipid bilayers. Multilamellar liposomes have at least two layers of lipids.
[0017] Preferred liposomes are those described herein, and in commonly owned U.S. patent application Ser. No. 10/366,584, filed on Feb. 12, 2003, the disclosure of which is incorporated herein in its entirety, by this reference. However, those of ordinary skill in the art will recognize that other formulations of liposomes may be utilized, including
phosphatidyl compounds, such as phosphatidylglycerol, phosphatidylcholine,
phosphatidylserine, phosphatidylethanolamine, sphingolipids, cerebrosides, and gangliosides. Particularly useful are diacylphosphatidylglycerols, where the lipid moiety contains from 14- 18 carbon atoms, particularly from 16-18 carbon atoms, and is saturated. Illustrative phospholipids include egg phosphatidylcholine, dipalmitoylphosphatidylcholine and distearoylphosphatidylcholine. Such lipids will also be useful in non- vesicular topical carrier compositions of the invention.
[0018] The size of liposomes and lipid vesicles utilized in the present invention, if any, may be variable, but such vesicles are preferably of uniform size in each batch preparation. The liposomes may be up to 20 um, 25 μιτι, or even 30 μπι. But in preferred embodiments about 95% of the liposomes will be from about 0.5 um to about 10 μπι in diameter. In one embodiment, at least 80% of liposomes in a preferred composition manufactured according to the methods described herein are from about 0.5 μηι to about 5 μηι. In this respect, the term "about" encompasses a range of 5% upwards or downwards from the stated value. The actual diameters of the liposomes will be a function of the cooling curve followed and the length and vigor of stirring or vortex hydration, when those processes are used in the manufacture of the liposomes. In still other embodiments, the liposomes can be multilamellar liposomes where a single larger liposome encapsulates one or more smaller liposomes.
[0019] Conventional liposomes manufactured according to means well known in the art may be used in the invention, but the preferred liposomes of the present invention do not contain a lipid soluble preservative as found in liposomes of the prior art (see, e.g., U.S. Pat. Nos. 4,761,288 and 4,897,269, both to Mezei, are both hereby incorporated by reference in their entirety). Indeed, the compositions of the invention will preferably be preservative-free although, if necessary to the storage conditions, a water-soluble preservative may be utilized, such as a benezoic acid or a benzethonium salt (e.g., benzethonium chloride) or, most preferably, an oil-insoluble product such as DOWCIL™ 200 (oil-insoluble 96% cis l-(3- chloroallyl)-3,5,7-triaza-l-azoniaadamantane chloride, Dow Biocides) or similar products known in the art, including other DOWCIL™ branded products.
[0020] However prepared, compositions of the invention do not include any
methylcellulose or any other viscosity enhancing or gelling agents. By "viscosity enhancing or gelling agents" is meant an agent that is added to the composition to increase the viscosity. A viscosity enhancing agent will increase the viscosity of a composition by at least 10,000 centipoise at 25° C. Viscosity enhancing agents include, but are not limited to, methyl cellulose, hydroxypropyl methyl cellulose (HPMC), alginic acid, gelatin, acacia (gum Arabic) carbomer, and cetostearyl alcohol. Phospholipids are not considered viscosity enhancing agents within this definition.
[0021] If the liposome is a phospholipid based vesicle, a preferred lipid will be
phospholipon 90H, which is obtained and purified from soy lecithin and has the chemical name l,2-dia-cyl-5N-glycero-3 -phosphatidyl choline. It is minimum 90% phophatidyl choline and is fully hydrogenated. But the person of ordinary skill will realize that other lipids may also be used in the present invention. For example, the phosphatidylcholine can be of lower purity, or can contain other lipids or carrier materials such as, for example, propylene glycol/ethanol, medium chain triglycerides, oil/ethanol, phosphatidic acid, cholesterol, and phosphatidylinositol. The phospholipid may be any natural or synthetic phospholipid, for example phosphatidylethanolamine, phosphatidylserine,
phosphatidylinositol, phosphatidylglycerol, phosphatidic acid, lysophospholipids, egg or soybean phospholipid or a combination thereof. The phospholipid may be salted or desalted, hydrogenated or partially hydrogenated, natural, synthetic, or semisynthetic. Examples of commercially available phospholipids include but are not limited to egg phospholipids PI 23 (Pfanstiehl, Waukegen, 111.), Lipoid E80 (Lipoid, Ludwigshafen, Germany); and the hydrogenated soy phospholipids Phospholipon 80H®, 80G®, 90H® and 100H®
(Nattermann, Munich, Germany) and 99% pure soy phosphatidyl choline (Avanti Polar Lipids, Alabaster, Ala.).
[0022] Optionally, dehydrated alcohol and propylene glycol can be used as co-solvents of the lipid phase, and vitamin E acetate can be included as an anti-oxidant. In various embodiments, other lipids or lipid-like substances are used in the invention, such as ceramides, lecithins, phosphatidyl ethanolamines, phosphatidyl serines, cardiolipins, trilinoleins and like compounds. Nonphospholipids may also be used in the present invention. For example, nonphospholipid materials that may be useful include lipid vesicle forming polyoxyethylene fatty esters, polyoxyethylene fatty acid ethers, diethanolamines, long-chain acyl amides, long-chain acyl amino acid amides, long-chain acyl amides, polyoxyethylene sorbitan oleates, polyoxyethylene glycerol monostearates, glycerol monostearates, and mixtures, analogs, and derivatives thereof. The vesicles may also include a steroid, and a charge producing agent. Preferred steroids include cholesterol, hydrocortisone, and analogs, derivatives, and mixtures thereof. Preferred negative charge producing materials are oleic acid, dicetyl phosphate, palmitic acid, cetyl sulphate, retinoic acid, phosphatidic acid, phosphatidyl serine, and mixtures thereof. In order to provide a net positive charge to the vesicles when desired, long chain amines, e.g., stearyl amines or oleyl amines, long chain pyridinium compounds, e.g., cetyl pyridinium chloride, quaternary ammonium compounds, or mixtures of these can be used, so long as the lipid vesicle can carry sufficient quantities of the aqueous phase.
[0023] Other liposomal formulations, including non-phospholipid lipsomes, may be utilized in the invention. For general reference, the multiphase liposomal drug delivery system disclosed in U.S. Pat. No. 4,761,288, issued Aug. 2, 1988 to Mezei (the disclosure of which is incorporated herein for ease of reference), is an exemplary representative of liposome compositions that may be utilized in the invention. For use as a topical carrier, modification of the liposome (or other lipid vesicle utilized in the invention) to sterically stabilize the vesicle, or to provide for targeting, or to provide the vesicle (or other lipid-based carrier utilized) with slow release properties, may interfere with the topical activity of the composition, and is therefore not preferred.
[0024] There is no theoretical limit to the number of compounds that may be incorporated into a lipid-based carrier for use in the invention. However, as those of ordinary skill in the art are aware, encapsulation efficiency is generally greater in liposomal compositions having a relatively high lipid:water content and a lipid-soluble drug carried in a lipid phase may generally be provided in a higher concentration than a water-soluble drug carried in an aqueous phase.
[0025] For example, two or more ingredients can be encapsulated in the same vesicle, or if the active compounds are incompatible, the compounds can be encapsulated separately and the topical carrier compositions combined to provide a composition with two or more indications, or that treats a single indication with multiple active compounds.
[0026] It is also possible to contemporaneously treat the external auditory canal by administering a topical carrier composition including one or more active compounds for treatment of the outer ear canal encapsulated in a vesicle, and a second set of one or more active compounds for treating the auditory canal dispersed in unencapsulated form in a surrounding water phase. Or, alternatively, non-vesicular lipids may be present, and all actives not encapsulated.
[0027] Preferably, compositions of the invention are provided in a slow release form, such as in liposomes manufactured to resist degradation. Those of ordinary skill in the art will be familiar with methods of manufacture that will accomplish this goal including, without limitation, addition of cholesterol to the lipid phase (see, e.g., U.S. Pat. No. 6,352,716, incorporated herein by reference as an illustration of a method for incorporating cholesterol into liposomes to this end).
[0028] Such relatively insoluble lipid vesicles can be expected to remain where delivered, to slowly release one or more of the active agents. Such vesicles may also have disinfectant or other properties helpful in treating or controlling the rate of infection in the outer ear; e.g., if hexadecyl trimethylammonium bromide, a potent disinfectant, is utilized as a positive charge producing material within the vesicles provides a secondary advantage. In such embodiments, the vesicles act as a sustained release formulation as they each deteriorate.
C. Useful Active agents for Treatment and Prophylaxis of Otitis Externa
[0029] By "active agent" is meant any biologically active compound useful in the treatment and/or prevention of otitis externa and its sequalae, as well as associated pain and inflammation. In this respect, therefore, particularly preferred medicaments are antibiotics useful in the treatment or prevention of otitis externa in mammals, especially humans.
Depending on the severity of the condition and its cause, such antibiotics include, without limitation, amoxicillin (and other penicillins), ciprofloxacin (and other quinolone antibiotics, such as ofloxacin), clavulanate (and other beta-lactamase inhibitors), cefaclor (and other cephalosporins, such as cefixime), azithromycin (and other macrolide antibiotics, such as clarithromycin), and sulfisoxazole (as well as other sulfa drugs, such as sulfamethoxazole). Of the antibiotics useful in the invention, those that are highly lipid soluble, which may be water insoluble, are preferred, with thiamphenicol and its analogues (e.g., chloramphenicol) being especially preferred.
[0030] Preferably, compositions of the invention will contain multiple agents useful in treating otitis externa including, without limitation, anti-fungal and anti-inflammatory compounds. Useful anti-inflammatory compounds for co-administration or use independent of antibiotic therapy include those that are sometimes less effective or well-tolerated in oral administration; e.g., non-steroidal anti-inflammatory drugs (NSAIDs), such as diclofenac, naproxen, ketoprofen, celecoxib, indomethacin, and pharmaceutically acceptable derivatives thereof. Steroidal compounds may be administered as an alternative or additive to a NSAID when clinically indicated (e.g., in chronic cases of otitis externa with pruritis), but are not required for use in the invention. Where present, the steroid may be betamethasone, betamethasone dipropionate, fluocinonide, fluocinoline acetonide, hydrocortisone, methylprednisolone, clobetasol, beclomethasone, dexamethasone sodium phosphate, triamcinolone and pharmaceutically acceptable derivatives thereof.
[0031] In preferred embodiments, the pharmaceutically active agents provided will include an anti-fungal agent. Suitable anti-fungal agents primarily include those that act on the cell wall or membrane of the fungi, although others (e.g., intracellularly acting agents) may also be suitable when clinically indicated. In general, cell wall/membrane active antifungals include the allylamines, the azoles, the polyene antimicotics, and the echinocandins. Non-limiting specific examples include terbinafine, miconazole, ketoconazole,
amphotericins, fluconazole, flucytosine, natamycin, amphotericin B, nystatin, cromolyn, lodoxamide, levocabastin, naphazolin, antazoline, pheniramimane and pharmaceutically acceptable derivatives thereof. Unless its use is contraindicated (e.g., for certain lupus patients), terbinafine is the presently preferred anti-fungal agent for use in the invention.
[0032] In some embodiments the pharmaceutically active agent may also include a local anesthetic or analgesic agent. Examples of suitable agents include benzocaine, benzyl benzoate, bupivacaine, calamine, chloroprocaine, chloroxylenol, cinchocaine, cocaine, dexivacaine, diamocaine, dibucaine, dyclonine, etidocaine, hexylcaine, ketamine, levobupivacaine, lidocaine, menthol, mepivacaine, oxethazaine, phenol, pramoxine, prilocaine, amethocaine, tetracaine, proparacaine, propoxycaine, pyrrocaine, resorcinol, risocaine, rodocaine, ropivacaine, tetracaine, and pharmaceutically acceptable derivatives thereof. Due to the rapid action of the compositions of the invention in resolving treated otitis externa, use of such anesthetic or analgesics may be unnecessary.
[0033] In animals especially, otitis externa is often linked to a parasitic infestation, most often an otocariosis, or Otodectes cynotis (ear mites) infestation. Topical treatment with ear mites has often been accomplished with relatively long courses of topical insecticidal therapy; e.g., with a pyrethrin-containing composition. However, shorter courses of therapy have been more recently obtained with mectin and mycin compounds; e.g., avermectins (such as ivermectin and selamectin) and milbemycin, administered otically, by injection, or on the skin. If clinically indicated, such anti-parasiticidal compounds may be co-administered within, or as a separate adjunct to, the compositions of the invention. Further, where clinically indicated, anti- viral compounds, such as acyclovir, may be administered in lieu of, or as an adjunct to, antibiotic compounds.
[0034] The following examples illustrate preparation and use of a preferred composition of the invention to treat otitis externa in dogs. As demonstrated, the condition was resolved in most animals with a single dose course of treatment. Animals who continued to show signs of the condition at day 14 following treatment were given another dose, and the condition resolved.
[0035] It will of course be appreciated that the invention may be utilized to treat otitis externa in any mammal, in whom the pharmaceutically acceptable, cellulose-free, non-gelled compositions of the invention will be applied topically to the outer ear canal in a dose sufficient to clinically ameliorate (significantly reduce symptoms to susceptibility to resolution with re-treatment, preferably a single dose re-treatment) or to resolve the treated condition. While physicians and veterinarians will of course be familiar with appropriate concentrations for dosing with individual active agents, the concentrations and dosing ranges expected to be efficacious in most clinical situations and species are 0.1 to 2.0% active w/w, delivered in unit dosages of up to about 1 mis., or 10-20 drops depending on the clinician's judgment of the appropriate course of treatment and the strength of the dosage delivered.
[0036] The invention having been fully described, the following examples are intended to illustrate, not to limit, the scope of the invention, which is defined by the appended claims. EXAMPLE 1
ANTIBIOTIC, ANTI-FUNGAL, NSAID-CONTAINING COMPOSITION OF THE
INVENTION
[0037] The lipid carrier was prepared with phospholipon 90H, and the active/inactive ingredients listed admixed therewith to a volume of lOOg as follows.
[0038] For preparation of the aqueous phase, water was added to a stainless steel jacketed vortex hydration chamber mixing vessel. The vessel's chamber was covered to prevent evaporation of water and equipped with a bottom port and valve to regulate flow of material out of the vessel. For Formulation IB, the DOWCIL™ 200 was added and dissolved into the water. For both formulations, one-half of the thiamphenical was added and dissolved to the water, and heat applied to the mixture at 50°C.+- 2° C. Mixing was performed at low speed to avoid formation of a foam. As the mixture was heating, the diclofenac was added and mixed until dissolved. Once the mixture reached a temperature of 50° C.+- 2° C, the xanthan gum was slowly added to the vortex as mixing continued until all ingredients were dissolved or (as to the gum) fully hydrated. The temperature was raised and mixing completed when the mixture reached a temperature between 55°C and 60°C.
[0039] For preparation of the lipid phase, a second stainless steel jacketed mixing vessel was utilized in close proximity to the first. In this second vessel, mixing of the propylene glycol, alcohol, cholesterol, vitamin E acetate, terbinafine and the remaining half of the thiamphenicol with the phospholipon 90H was initially performed slowly to avoid formation of foam or surface bubbles. An overhead mixer was started and heat applied to raise the temperature of the mixture to between 55°C and 60°C until all were dissolved. A cover was used on the chamber to prevent evaporation of alcohol throughout the procedure.
[0040] The lipid phase was quickly added to the aqueous phase at medium mixing speed. In particular, valves were opened on the bottom ports of the chambers, and the flow was regulated from both vessels. The aqueous phase and oil phase flowed and met at an in-line regulating tee, and a dispersing pump pulled the two phases together. The mixture was circulated through a 60 mesh dispersing screen to optimize the hydration of the lipid phase. The mixture was then directed to the top of the chamber and the entire process was circulated through the pump, back into the chamber for 10 minutes.
[0041] After circulation, the chamber jacket was allowed to cool with continued slow mixing until the temperature of the product was 40° C, completing the process. The combination of materials is preferably fast enough to mix thoroughly without causing formation of surface foam or bubbling. The cooling process is preferably slow, with cooling of about 6°C per hour most preferable., by pouring or quickly pumping the former into the latter to mix them using bottom ports and tees. No heat was applied to the mixture. The formulations prepared were as follows.
FORMULATION 1A
Figure imgf000013_0001
[0042] The following composition, which included a preservative and a lower concentration of terbinafme, is slightly less efficacious, suggesting that lower concentrations of the anti-fungal agent may be utilized, still allowing for single dose resolution of treated ears. FORMULATION IB
Figure imgf000014_0001
EXAMPLE 2
TREATMENT OF OTITIS EXTERNA IN CANINES
[0043] Twenty-six dogs of varying breeds with confirmed otitis externa, including bacterial infection, fungal infestation and inflammation, were treated with a single dose of the compositions of Example 1 by dropper- wise administration of 20 drops per ear. Dogs 1-16 were given Formulation IB, while dogs 17-26 were given Formulation 1A. The treated ears were evaluated for signs of otitis externa at days 7 and 14 following dosing.
[0044] The endpoint for effectiveness was an clinical score improvement to 2 or less in both ears, with a presenting score of at least 6 per ear being a condition for admission of an animal into the study. The clinical scores were objectively assigned and evaluated by a clinician based on a standard scoring system for each of the following signs of otitis externa: pain, erythema, exudate, swelling, odor, and ulceration. The scores were assignable as follows: PAIN: 0=none, l=mild/moderate— painful on palpitation, 2-severe— painful on raising of the pinna. ERYTHEMA: 0=none, l=mild/moderate— barely noticeable to obvious redness on otoscopic evaluation, 2=severe— beet or bright red on examination and/or erythema extends into the pinna tissue. EXUDATE: 0=none, l=mild/moderate-— small amount visible in the ear canal, 2=severe— extends out of the ear canal and may be crusted. SWELLING: 0=none, l=mild/moderate— some occlusion of the ear canal, 2=severe— ear canal completely occluded. ODOR: 0=none, l=mild/moderate— malodor detectable when pinna is raised, 2=severe— malodor detectable without raising pinna. ULCERATION:
0=none, l=mild/moderate— mild abrasions visible, 2=severe— abrasions extensive and/or may be bleeding.
[0045] One animal treated with Formulation IB showed signs of particularly significant infection and was retreated at day 7. Yeast overgrowth was noted in two animals treated with Formulation IB at day 14, so they were also retreated. No retreatment of animals who received Formulation 1 A was required, although treatment was considered to fail (no significant amelioration or full recovery) in one such animal.
[0046] Overall, response to the treatment was not statistically significant in four animals by day 14. Possible reasons for treatment failure include presence of bacteria or fungus that wasn't susceptible to the active agents involved or other factors. In all four animals, the otitis externa presented as very severe, a 12 out of a scale of 12.
[0047] In nineteen of the animals, however, the otitis externa was completely resolved by day 14 following the single dose administered. All of those animals showed significant signs of improvement in the treated condition by day 7, including animals in whom the presenting condition was rated 12 on the 12 point scale.
Figure imgf000015_0001
10 Cinnamon 5/12 9 5/19 1 5/26 1 BBI
11 Chuck 5/12 11 !¾¾ 5/18 1 5/26 0 $¾β!1
12 Patches 5/14 12 5/20 2 5/28 0
13 Brigley 5/18 9 5/28 1 lill 6/3 0
14 Blanca 5/21 9 5/29 2 6/15 2
15 Angel 5/21 11 5/27 1 6/3 0 HB
16 Wiggles 5/26 12 m 6/2 3 6/9 6
17 Sophia 6/9 9 ϋ I S!
6/16 2 6/23 0
18 Nokie 6/10 8 H 6/15 2 6/22 0
19 Sasha 6/15 9 iiiift 6/23 0 B 7/1 0
20 Tank 6/17 12 6/24 2 7/1 2
21 Pearl 6/17 10 6/24 2 7/6 2 IBB
22 Bosco 6/18 12 6/22 3 7/6 0
23 Jasmine 6/22 12 n 6/29 0 7/8 0
24 Lucky Ws, 6/24 11 7/1 2 ||||» 7/8 4
25 Kittie 6/29 11 7/6 2 7/13 0
26 Marley 6/29 12 7/7 5 7/14 8 *
R = retreat
R{Y) = yeast, retreated
* = failed
[0048] The invention illustratively described herein may be practiced in the absence of any element or elements, limitation or limitations which is not specifically disclosed herein. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the appended claims.
[0049] The contents of the articles, patents, and patent applications, and all other documents and electronically available information mentioned or cited herein, are hereby incorporated by reference in their entirety to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference. Applicants reserve the right to physically incorporate into this application any and all materials and information from any such articles, patents, patent applications, or other documents.
[0050] The inventions illustratively described herein may suitably be practiced in the absence of any element or elements, limitation or limitations, not specifically disclosed herein. Thus, for example, the terms "comprising", "including," containing", etc. shall be read expansively and without limitation. Additionally, the terms and expressions employed herein have been used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the inventions embodied therein herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention.
[0051] The invention has been described broadly and genetically herein. Each of the narrower species and subgeneric groupings falling within the generic disclosure also form part of the invention. This includes the generic description of the invention with a proviso or negative limitation removing any subject matter from the genus, regardless of whether or not the excised material is specifically recited herein. Other embodiments are set forth within the following claims.
[0052] In addition, where features or aspects of the invention are described in terms of Markush groups, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group.
[0053] The scope of our invention is defined by the following claims.

Claims

What is claimed is:
1. A method for treating or preventing otitis externa infection and sequelae thereof by topical administration of a pharmaceutically acceptable composition to the outer ear canal, wherein said composition does not include viscocity-enhancing celluloses or adhesive components, and is not in the form of a gel, and wherein the composition comprises a lipid carrier and at least two active agents selected from the group consisting of antibiotics, antifungals, anti-parasitics, anti-virals, non-steroidal anti-inflammatories, analgesics, anesthetics and steroids, the method comprising applying the composition to the outer ear canal in a single dose sufficient to clinically ameliorate or resolve the treated condition.
2. The method according to claim 1, wherein the lipid carrier is a lipid vesicle.
3. The method according to claim 1, wherein one active agent in said composition is an antibiotic.
4. The method according to claim 1, wherein one active agent in said composition is an anti-fungal.
5. The method according to claim 1, wherein one active agent in said composition is a non-steroidal anti-inflammatory drug (NSAID).
6. The method according to claim 3, wherein the antibiotic is selected from the group consisting of quinolone antibiotics, penicillin antibiotics, macrolide antibiotics, cephalosporin antibiotics, sulfa antibiotics, and beta-lactamase inhibitors.
7. The method according to claim 6, wherein said antibiotic comprises thiamphenicol.
8. The method according to claim 4, wherein said anti-fungal is an allylamine antifungal agent.
9. The method according to claim 8, wherein the allylamine is terbinafine.
10. The method according to claim 5, wherein the NSAID is diclofenac.
11. The method according to claim 1 , wherein the active agents are an antibiotic, an antifungal and a NSAID.
12. The method according to claim 1 , wherein the antibiotic is thiamphenicol, the antifungal is terbinafine and the NSAID is diclofenac.
13. The method according to claim 12, wherein the terbinafine is provided in a concentration of 1 to 1.5% w/w of the composition.
14. The method according to claim 12, wherein the diclofenac is provided in a concentration of 0.5% w/w of the composition.
15. The method according to claim 12, wherein the composition further includes an oil- insoluble preservative.
PCT/US2010/056255 2009-11-11 2010-11-10 Methods and compositions for rapid treatment of otitis externa WO2011060083A1 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
UAA201207023A UA111147C2 (en) 2009-11-11 2010-10-11 METHODS AND COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF EXTERNAL OTITIS
AU2010319538A AU2010319538B2 (en) 2009-11-11 2010-11-10 Methods and compositions for rapid treatment of otitis externa
CA2780160A CA2780160C (en) 2009-11-11 2010-11-10 Tropical compositions for treating otitis externa infections
EP10830669.7A EP2498792B1 (en) 2009-11-11 2010-11-10 Compositions comprising phospholipid carriers for the treatment of otitis externa
BR112012011017A BR112012011017A2 (en) 2009-11-11 2010-11-10 processes and compositions for rapid treatment of otitis externa
CN201080051245.7A CN102612372B (en) 2009-11-11 2010-11-10 For the method and composition of fast treating external otitis
SI201031550T SI2498792T1 (en) 2009-11-11 2010-11-10 Compositions comprising phospholipid carriers for the treatment of otitis externa
MX2012005521A MX2012005521A (en) 2009-11-11 2010-11-10 Methods and compositions for rapid treatment of otitis externa.
DK10830669.7T DK2498792T3 (en) 2009-11-11 2010-11-10 COMPOSITIONS CONTAINING PHOSPHOLIPID CARRIERS FOR TREATMENT OF OTITIS EXTERNAL
PL10830669T PL2498792T3 (en) 2009-11-11 2010-11-10 Compositions comprising phospholipid carriers for the treatment of otitis externa
NO10830669A NO2498792T3 (en) 2009-11-11 2010-11-10
JP2012538954A JP2013510861A (en) 2009-11-11 2010-11-10 Methods and compositions for rapid treatment of otitis externa
RU2012124067A RU2680137C2 (en) 2009-11-11 2010-11-10 Method and composition for otitis externa treatment
LTEP10830669.7T LT2498792T (en) 2009-11-11 2010-11-10 Compositions comprising phospholipid carriers for the treatment of otitis externa
NZ599559A NZ599559A (en) 2009-11-11 2010-11-10 Methods and compositions for rapid treatment of otitis externa
KR1020177023631A KR101901083B1 (en) 2009-11-11 2010-11-10 Methods and compositions for rapid treatment of otitis externa
ES10830669.7T ES2645200T3 (en) 2009-11-11 2010-11-10 Compositions comprising phospholipid carriers for the treatment of otitis externa
IL219483A IL219483A (en) 2009-11-11 2012-04-30 Combinations of active agents for the preparation of medicaments for rapid treatment of otitis externa
ZA2012/03239A ZA201203239B (en) 2009-11-11 2012-05-04 Methods and compositions for rapid treatment of otitis externa
HRP20171520TT HRP20171520T1 (en) 2009-11-11 2017-10-10 Compositions comprising phospholipid carriers for the treatment of otitis externa

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26030909P 2009-11-11 2009-11-11
US61/260,309 2009-11-11

Publications (1)

Publication Number Publication Date
WO2011060083A1 true WO2011060083A1 (en) 2011-05-19

Family

ID=43992011

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/056255 WO2011060083A1 (en) 2009-11-11 2010-11-10 Methods and compositions for rapid treatment of otitis externa

Country Status (28)

Country Link
US (1) US8927006B2 (en)
EP (1) EP2498792B1 (en)
JP (2) JP2013510861A (en)
KR (2) KR20120116398A (en)
CN (1) CN102612372B (en)
AU (1) AU2010319538B2 (en)
BR (1) BR112012011017A2 (en)
CA (1) CA2780160C (en)
CL (1) CL2012001227A1 (en)
CO (1) CO6540004A2 (en)
DK (1) DK2498792T3 (en)
EC (1) ECSP12011967A (en)
ES (1) ES2645200T3 (en)
HR (1) HRP20171520T1 (en)
HU (1) HUE034617T2 (en)
IL (1) IL219483A (en)
LT (1) LT2498792T (en)
MX (1) MX2012005521A (en)
MY (1) MY162687A (en)
NO (1) NO2498792T3 (en)
NZ (1) NZ599559A (en)
PL (1) PL2498792T3 (en)
PT (1) PT2498792T (en)
RU (1) RU2680137C2 (en)
SI (1) SI2498792T1 (en)
UA (1) UA111147C2 (en)
WO (1) WO2011060083A1 (en)
ZA (1) ZA201203239B (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014036165A1 (en) * 2012-08-29 2014-03-06 Bayer Healthcare, Llc Aqueous based compositions for treating otitis externa
CN104337952A (en) * 2013-08-10 2015-02-11 李谊 Combined medicine for treating explosive deafness by combining traditional Chinese medicines and western medicine
CN104739768A (en) * 2013-12-27 2015-07-01 河南惠通天下生物工程有限公司 Thiamphenicol nanoliposome and preparation method thereof
EP3482744A1 (en) * 2017-11-14 2019-05-15 ProFem GmbH Emulsions for the topical treatment of urogenital and dermal infections
WO2019096863A1 (en) 2017-11-14 2019-05-23 Profem Gmbh Emulsions for the topical treatment of dermal infections and mucosal infections
US11801221B2 (en) 2019-09-23 2023-10-31 Dds Research Inc. Lipid vesicle compositions with penetration enhancing agents

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11986483B2 (en) * 2019-10-11 2024-05-21 Dechra Veterinary Products, Llc Otic formulations, methods and devices
CN113876658B (en) * 2021-11-01 2023-10-20 仙乐健康科技股份有限公司 Oil-in-water emulsion composition and method for producing same

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080206161A1 (en) * 2002-10-25 2008-08-28 Dov Tamarkin Quiescent foamable compositions, steroids, kits and uses thereof
US20090005339A1 (en) * 2005-03-10 2009-01-01 Scholz Matthew T Methods of Treating Ear Infections
US20090082337A1 (en) * 2007-09-21 2009-03-26 Srini Venkastesh Compositions Comprising Quinolone and Methods for Treating or Controlling Infections
US20090111780A1 (en) * 2007-10-31 2009-04-30 Everett Laboratories, Inc. Compositions and methods for treatment of ear canal infection and inflammation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69528355T2 (en) * 1994-02-04 2003-05-15 Lipocore Holding Ab Stockholm DOUBLE-LAYER COMPOSITIONS OF DIGALACTOSYL DIACYLGLYCEROL CONTAINING GALACTOLIPID
CA2201134A1 (en) * 1994-10-10 1996-04-18 Alfred Sallmann Ophthalmic and aural compositions containing diclofenac potassium
PT782448E (en) * 1995-06-06 2002-07-31 Bayer Ag NON-IRRITATING, NON-OTOTOXIC ANTIBACTERIAL OTIC FORMULATIONS
IT1295369B1 (en) 1997-10-21 1999-05-12 Fatro Spa COMPOSITION BASED ON TIAMFENICOLO AND DICLOFENAC
US6433024B1 (en) * 2000-05-08 2002-08-13 Karl F. Popp Topical anti-acne composition
AUPR798901A0 (en) * 2001-09-28 2001-10-25 Medvet Science Pty. Ltd. Spheroidal hdl particles with a defined phospholipid composition
US20050013854A1 (en) * 2003-04-09 2005-01-20 Mannino Raphael J. Novel encochleation methods, cochleates and methods of use
EP1651210A1 (en) 2003-07-31 2006-05-03 Pharmacia & Upjohn Company LLC Dispersible formulation of an anti-inflammatory agent
US20050159369A1 (en) 2003-08-20 2005-07-21 Qtm Llc Method of treatment of otitis externa
US20070078116A1 (en) 2003-08-20 2007-04-05 Fairfield Clinical Trials, Llc Method of treatment of otitis externa
US20070054844A1 (en) 2003-08-20 2007-03-08 Fairfield Clinical Trials, Llc Method for treating otitis externa
EP1784164A4 (en) 2004-09-03 2008-07-09 Piedmont Pharmaceuticals Llc Methods for transmembrane treatment and prevention of otitis media

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080206161A1 (en) * 2002-10-25 2008-08-28 Dov Tamarkin Quiescent foamable compositions, steroids, kits and uses thereof
US20090005339A1 (en) * 2005-03-10 2009-01-01 Scholz Matthew T Methods of Treating Ear Infections
US20090082337A1 (en) * 2007-09-21 2009-03-26 Srini Venkastesh Compositions Comprising Quinolone and Methods for Treating or Controlling Infections
US20090111780A1 (en) * 2007-10-31 2009-04-30 Everett Laboratories, Inc. Compositions and methods for treatment of ear canal infection and inflammation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2498792A4 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014036165A1 (en) * 2012-08-29 2014-03-06 Bayer Healthcare, Llc Aqueous based compositions for treating otitis externa
CN104337952A (en) * 2013-08-10 2015-02-11 李谊 Combined medicine for treating explosive deafness by combining traditional Chinese medicines and western medicine
CN104739768A (en) * 2013-12-27 2015-07-01 河南惠通天下生物工程有限公司 Thiamphenicol nanoliposome and preparation method thereof
EP3482744A1 (en) * 2017-11-14 2019-05-15 ProFem GmbH Emulsions for the topical treatment of urogenital and dermal infections
WO2019096863A1 (en) 2017-11-14 2019-05-23 Profem Gmbh Emulsions for the topical treatment of dermal infections and mucosal infections
US11266600B2 (en) 2017-11-14 2022-03-08 Profem Gmbh Emulsions for the topical treatment of dermal and mucosal infections
US11801221B2 (en) 2019-09-23 2023-10-31 Dds Research Inc. Lipid vesicle compositions with penetration enhancing agents

Also Published As

Publication number Publication date
ECSP12011967A (en) 2012-08-31
UA111147C2 (en) 2016-04-11
LT2498792T (en) 2017-10-25
KR20120116398A (en) 2012-10-22
NZ599559A (en) 2014-08-29
MX2012005521A (en) 2012-06-19
EP2498792B1 (en) 2017-08-02
US20110281809A1 (en) 2011-11-17
HRP20171520T1 (en) 2017-11-17
DK2498792T3 (en) 2017-11-06
PL2498792T3 (en) 2018-01-31
CA2780160C (en) 2018-03-06
EP2498792A1 (en) 2012-09-19
HUE034617T2 (en) 2018-02-28
CO6540004A2 (en) 2012-10-16
MY162687A (en) 2017-07-14
RU2012124067A (en) 2013-12-20
NO2498792T3 (en) 2017-12-30
PT2498792T (en) 2017-10-18
AU2010319538A1 (en) 2012-05-17
CN102612372A (en) 2012-07-25
SI2498792T1 (en) 2017-11-30
BR112012011017A2 (en) 2015-09-15
US8927006B2 (en) 2015-01-06
CL2012001227A1 (en) 2012-08-24
ES2645200T3 (en) 2017-12-04
KR20170100680A (en) 2017-09-04
JP2016102112A (en) 2016-06-02
RU2680137C2 (en) 2019-02-18
CN102612372B (en) 2016-01-20
AU2010319538B2 (en) 2015-04-09
ZA201203239B (en) 2013-07-31
JP2013510861A (en) 2013-03-28
IL219483A0 (en) 2012-06-28
EP2498792A4 (en) 2013-06-12
IL219483A (en) 2017-12-31
KR101901083B1 (en) 2018-09-20
CA2780160A1 (en) 2011-05-19
JP6138891B2 (en) 2017-05-31

Similar Documents

Publication Publication Date Title
US8927006B2 (en) Methods and compositions for rapid treatment of otitis externa
Abdelkader et al. Recent advances in non-ionic surfactant vesicles (niosomes): self-assembly, fabrication, characterization, drug delivery applications and limitations
US20080124385A1 (en) Methods for Transmembrane Treatment and Prevention of Otitis Media
US8834921B2 (en) Sustained-release liposomal anesthetic compositions
Bavarsad et al. Colloidal, in vitro and in vivo anti-leishmanial properties of transfersomes containing paromomycin sulfate in susceptible BALB/c mice
JP4991530B2 (en) Phospholipid gel composition for drug delivery and method of treating symptoms using the same
JP2002533379A (en) Improved formulation for locally non-invasive use in vivo
US20030235610A1 (en) Liposomes containing biologically active compounds
WO2013146386A1 (en) Sustained-release local anesthetic preparation
MX2010005862A (en) Compositions and methods for the treatment of bladder cancer.
Mori et al. In vivo antitumor activity of cis-bis-neodecanoato-trans-R, Rl, 2-diaminocyclohexane platinum (II) formulated in long-circulating liposomes
US20120207821A1 (en) Liposomal formulation and use thereof
JP4966855B2 (en) Sterol-enriched mixed layered amphotericin-inserted liposome in saline and method for preparing the same
JPH05506671A (en) Drugs to treat viral diseases
RU2820649C2 (en) Sustained release anesthetic compositions and methods for preparation thereof
JPH05506670A (en) Drugs to treat viral diseases
CN101031282A (en) Methods for transmembrane treatment and prevention of otitismedia
Bahe et al. ETHOSOMES: A POTENTIAL CARRIER FOR ENHANCING TRANSDERMAL DRUG DELIVERY

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080051245.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10830669

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2010319538

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2780160

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12012500913

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2012001227

Country of ref document: CL

Ref document number: 2012538954

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1201002151

Country of ref document: TH

Ref document number: MX/A/2012/005521

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2010319538

Country of ref document: AU

Date of ref document: 20101110

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20127013348

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12092192

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 4973/CHENP/2012

Country of ref document: IN

REEP Request for entry into the european phase

Ref document number: 2010830669

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: A201207023

Country of ref document: UA

Ref document number: 2010830669

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2012124067

Country of ref document: RU

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012011017

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112012011017

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20120509